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ABSTRACT 
Lynch syndrome (LS) is an autosomal-dominant 
disease characterized by an increased cancer 
susceptibility, particularly of the colon and 
endometrium. LS is caused by a constitutional 
heterozygous loss-of-function mutation or 
epimutation in one of the DNA mismatch repair 
(MMR) genes (MLH1, MSH2, MSH6 or PMS2). 
Loss of MMR activity leads to an accumulation of 
DNA replication errors, especially in repetitive 
sequences, a phenomenon referred to as 
microsatellite instability (MSI). MSI occurs in the 
majority of LS cancers and is a hallmark of the 
disease. The lifetime risk of cancers in individuals 
with LS varies dependent on gender and on which 
MMR gene is mutated. Intensive colorectal 
screening is proven to be effective in reducing 
colorectal cancer-related mortality in LS patients. 
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Identity 
Other names 
Hereditary Non-polyposis Colorectal Cancer, 
HNPCC 
Note 
Inherited cancer susceptibility syndrome 
characterized by a high risk of developing colorectal, 
endometrial and other malignancies. 
Inheritance 
Autosomal dominant with incomplete penetrance 
and variable expressivity; the cumulative lifetime 
risk of cancers is gender-related and dependent on 
which MMR gene is mutated. The prevalence of LS 
has been estimated between one in 370 and one in 
3.100 people of the general population (Stormorken 
et al., 2007; Jarvinen et al., 2009). 
Clinics 
Note 
The term Lynch Syndrome is correctly applied to 
families and patients with a germline defect in one of 
the MMR genes; this designation is more appropriate 
than HNPCC (Hereditary Non-Polyposis Colorectal 
Cancer) because LS patients could develop also 
some colorectal polyps, which makes the word 
"nonpolyposis" ambiguous. 
The MMR pathway normally maintains fidelity of 
the DNA during replication by correction of single 
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base pair mismatches and small insertion or deletion 
loops (Kunkel and Erie, 2005). LS-related cancers 
form when a somatic loss of the remaining wild type 
allele occurs; this results in loss of MMR activity and 
subsequent MSI in tumour tissue. The MSI, as well 
as the negative immunohistochemical staining for 
the protein encoded by the mutated MMR gene, 
occurs in over 90% of LS-related cancers. 
Phenotype and clinics 
Colorectal cancer(CRC) is the most common 
malignancy in LS patients. LS-associated CRCs are 
characterized by an early age of onset (44-61 years 
versus 69 years in sporadic cases (Giardiello et al., 
2014)); this earlier presentation is related to a more 
rapid adenoma-carcinoma sequence. Moreover, 
CRCs in LS patients frequently occur on the right 
side of the colon (Lynch et al., 1993; Lynch and 
Smyrk, 1996; Aarnio et al., 1999) and tend to be 
mucinous, poorly differentiated and with tumour-
infiltrating lymphocytes (Kastrinos and Stoffel, 
2014). Noteworthy, a high rate of metachronous 
CRCs after segmental colectomy has been described 
with a cumulative risk of 16% at 10 years and 41% 
at 20 years (Parry et al., 2011).  
 
Endometrial carcinoma (EC) is the second most 
frequent cancer occurring in women with LS and is 
characterized by a young age at onset, with an 
average age at diagnosis of 48 years compared with 
62 years in sporadic EC (Vasen et al., 2014; Hampel 
et al., 2005).  
 
LS patients are also predisposed to $ (generally 
intestinal-type) and ovarian cancer  (particularly 
with endometrioid / clear cell histology), with a 
mean age at diagnosis of 56 and 42.5 years, 
respectively (Aarnio et al., 1997; Capelle et al., 
2010; Watson et al., 2008; Helder-Woolderink et al., 
2016).  
 
Less common LS-related malignancies include those 
of the urinary tract ( transitional cell carcinomas), 
small bowel, hepatobiliary tract, glioblastomas and 
cutaneous sebaceous neoplasms (Bonadona et al., 
2011; Kohlmann and Gruber, 2014). 
Differential Diagnosis 
 Familial CRC.  This definition is used to describe 
families characterized by a cluster of CRCs not 
apparently related to a known hereditary CRC 
syndrome. Familial CRC is a heterogeneous 
condition that can be caused in part by a combination 
of genetic and environmental factors.  
 
 Attenuated familial adenomatous polyposis 
(AFAP).  The attenuated form of APC-related 
polyposis is characterized by fewer polyps and later 
age of onset than classic FAP. Extracolonic 
manifestations (e.g., gastric and duodenal polyps, , 
dental anomalies, congenital hypertrophy of the 
retinal pigment epithelium and desmoid tumours) 
could be variably present. Polyps and CRCs 
associated with AFAP do not exhibit MSI 
 
 MUTYH-Associated polyposis (MAP).   The 
colonic phenotype of MAP can be similar to 
attenuated FAP but the inheritance is autosomal 
recessive. A minority of individuals with MAP 
presented with CRC and few or no polyps (Croitoru 
et al., 2004: Farrington et al., 2005; Balaguer et al., 
2007; Cleary et al., 2009).  
 
 Hamartomatous polyposis syndromes.   These 
conditions are characterized by an increased risk of 
CRC but can be recognized by the presence of 
hamartomatous polyps and extracolonic 
manifestations.  
 
 Hereditary diffuse gastric cancer.  CDH1-related 
gastric cancers are typically diffuse or with signet-
ring histology.  
 
 BRCA1/BRCA2 hereditary breast-ovarian 
cancer.  This condition should be suspected when 
the personal and/or family history includes ovarian 
cancer. 
Neoplastic risk 
In MLH1 and MSH2 gene mutation carriers, the 
lifetime risk of CRC ranges from 30% to 74% 
(Giardiello, 2014). Lower risk for CRC has been 
estimated in patients with MSH6 and PMS2 
mutation, ranging from 10% to 22% (Hendriks et al., 
2004; Senter et al., 2008).  
 
EC occurs in up to 70% of women with MSH6 
mutations; lower risks are described in those with 
MLH1 and MSH2 mutations (54%) and with PMS2 
mutations (15%) (Giardiello et al., 2014; Hendriks et 
al., 2004; Senter et al., 2008).   
 
Concerning ovarian cancer, the reported lifetime 
risks in women with LS range from 6.7% to 12% and 
appear to be higher for carriers of MSH2 mutations 
(Watson et al., 2008; Engel et al., 2012; Bonadona et 
al., 2011).  
 
Gastric cancer is reported to occur in approximately 
5%-13% of LS patients, with considerable 
variability based on country of origin (Watson et al., 
2008; Capelle et al., 2010).  
 
The risk for other LS-related cancers is lower, 
though increased over general population rates. 
Treatment 
Colorectal surveillance is the only surveillance 
protocol proved to be effective in LS patients. 
Colonoscopy is recommended every one to two 
years beginning between ages 20 and 25 years or two 
to five years before the earliest age of diagnosis in 
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the family, whichever is earlier (Giardiello et al., 
2014; NCCN, 2017). Screening for CRC by 
colonoscopy has been shown to decrease CRC-
related mortality by 72% (Dove-Edwin et al., 2005) 
and has been associated with lower risk of CRC and 
an earlier stage at diagnosis (Parry et al., 2011; 
Vasen et a., 2010; Engel et al., 2010; Stuckless et al., 
2012).  
 
The evidence for efficacy of surveillance for cancer 
of the endometrium, ovary, stomach, duodenum and 
urinary tract is limited.  
 
Prophylactic removal of the colon is generally not 
recommended for individuals with LS because 
routine colonoscopy is an effective preventive 
measure. If a CRC is detected, full colectomy with 
ileorectal anastomosis might be considered because 
of the high risk for metachronous cancers.  
Prophylactic removal of the uterus and ovaries can 
be considered after childbearing is completed.   
 
Growing but not conclusive evidence exists on the 
use of aspirin for prevention of cancer in LS patients 
(Burn et al., 2011; Rothwell et al., 2011).  The 
potential benefits, risks and current limitations of 
available uncertainties of aspirin therapy should be 
discussed with LS patients. 
Prognosis 
Colonoscopic surveillance with early detection and 
treatment of invasive CRC is associated with 
excellent survival (Moller et al., 2015). When 
matched stage for stage, LS CRCs are associated 
with a better prognosis compared with sporadic 
CRCs (Watson et al., 1998; Gryfe et al., 2000).  
 
LS-related EC or ovarian cancer have also a good 
prognosis when given current treatment (Moller et 
al., 2015). 
Genes involved and 
proteins 
Gene 
MLH1 (mutL homolog 1) 
Location 
3p22.2 
DNA/RNA 
Description 
The MLH1 gene is 72,558 bases in length, with 19 
coding exons. 
Transcription 
The transcribed mRNA has 2524 bps. 12 distinct 
transcripts have been described. 
Protein 
Description 
Size: 756 aminoacids; Molecular Mass: 84,601 Da. 
It contains an ATPase domain and three interaction 
domains, one for MutS homologs, one for PMS2, 
MLH3 or PMS1 and the other for EXO1. 
Expression 
Ubiquitous 
Localisation 
Nucleoplasm 
Function 
The MLH1 protein dimerizes with PMS2 protein to 
form MutL alpha, a component of the post-
replicative DNA mismatch repair (MMR) system. 
The MutL alpha heterodimer possesses an 
endonucleolytic activity that is activated following 
the recognition of DNA mismatches and 
insertion/deletion loops by MutS alpha (composed of 
MSH2 and MSH6) or MutS beta (composed of 
MSH2 and MSH3). MutL-MutS complex is 
responsible for the recruitment of other proteins 
involved in MMR.  
 
The MLH1 protein can also bind to PMS1 or MLH3 
to form MutL beta and MutL gamma respectively. 
MutL beta and gamma heterodimers are probably 
components of the MMR system. 
Homology 
MLH1 is homolog of the E. coli DNA mismatch 
repair gene mutL and MLH1 homologs are also 
present in eukaryotes. 
Mutations 
Germinal 
More than 200 different pathogenic variants have 
been reported. MLH1 mutations are responsible of 
35-40% cases of Lynch Syndrome (LS). Nonsense, 
missense and splice-site mutations predominate, 
whereas large genomic rearrangements constitute A 
and exon 16 deletion account for 50% of LS families 
in Finland) (Lynch et al., 2009). 
Somatic 
The most frequent cause of microsatellite instability 
(MSI) and loss of MLH1 and PMS2 
immunohistochemical expression is the somatic 
methylation of the promoter region of MLH1 that 
silences gene expression in the tumour tissue. 
Epigenetics 
Constitutional inactivation of MLH1 by 
hypermethylation has been reported as a rare cause 
of LS (< 1%). Most of such cases are sporadic and 
not heritable, but a few cases of inherited 
hypermethylation have been reported (Goel et al., 
2011; Peltomaki, 2014; Hitchins, 2016). 
Gene 
MSH2 (mutS homolog 2) 
Location 
2p21-p16.3 
DNA/RNA 
Description 
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he MSH2 gene is 159,343 bases in length, with 16 
coding exons. 
Transcription 
The transcribed mRNA has 3145 bps. 9 distinct 
transcripts have been described. 
Protein 
Description 
Size: 934 aminoacids; Molecular Mass: 104,743 Da. 
It contains a DNA binding domain and two 
interaction domains, one for MSH3 or MSH6 and the 
other for MutL homologs (composed of MLH1 and 
PMS2). 
Expression 
Ubiquitous 
Localisation 
Nucleoplasm. 
Function 
The MSH2 protein forms an heterodimer with either 
MSH6 (MutS alpha) or MSH3 (MutS beta) and 
identifies DNA mismatches. While MutS alpha 
complex recognizes single base mismatches and 
dinucleotide insertion-deletion loops in the DNA, 
MutS beta recognizes larger insertion-deletion loops. 
A sliding clamp model has been suggested to 
describe the structure of these heterodimers. 
After mismatch binding, MutS alpha or beta 
associates with the MutL alpha heterodimer 
(composed of MLH1 and PMS2): MutL-MutS 
complex is responsible for the recruitment of other 
proteins involved in MMR. 
Homology 
MSH2 is homolog of the E. coli DNA mismatch 
repair gene mutS and MSH2 homologs are also 
present in eukaryotes. 
Mutations 
Germinal 
More than 170 different pathogenic variants have 
been reported. MSH2 mutations are responsible of 
44-48% cases of Lynch Syndrome (LS). Nonsense, 
missense and splice-site mutations predominate, but 
large genomic rearrangements constitute >20% of 
the alterations. The higher proportion of Alu repeats 
may contribute to the higher rate of genomic 
rearrangements in MSH2 than in MLH1. There are 
also MSH2 founder mutations which account for a 
high proportion of LS families in some specific 
populations (e.g. exons 1-6 deletion in United States) 
(Lynch et al., 2009). 
Somatic 
Microsatellite instability (MSI) and loss of MSH2 
and MSH6 immunohistochemical expression can 
also be due to somatic mutations in MSH2 gene. 
Epigenetics 
Germline deletions of the 3' end of EPCAM gene can 
lead to inactivation of the MSH2 promoter through 
hypermethylation and, therefore, are a rare cause of 
LS (< 3%). 
Gene 
MSH6 (mutS homolog 6) 
Location 
2p16.3 
DNA/RNA 
Description 
The MSH6 gene is 23,871 bases in length, with 10 
coding exons. 
Transcription 
The transcribed mRNA has 4263 bps. 10 distinct 
transcripts have been described. 
Protein 
Description 
Size: 1360 aminoacids; Molecular Mass: 152,786 
Da. It contains a highly conserved helix-turn-helix 
domain associated with a Walker-A motif (an 
adenine nucleotide and magnesium binding motif) 
with ATPase activity. 
Expression 
Ubiquitous 
Localisation 
Nucleoplasm 
Function 
The MSH6 protein dimerizes with MSH2 to form 
MutS alpha and functions in the identifications of 
single base mismatches and dinucleotide insertion-
deletion loops in the DNA by a sliding clamp model.  
 
MutS alpha associates with the MutL alpha 
heterodimer (composed of MLH1 and PMS2): 
MutL-MutS complex is responsible for the 
recruitment of other proteins involved in MMR. 
Homology 
MSH6 is homolog of the E. coli DNA mismatch 
repair gene mutS and MSH6 homologs are also 
present in eukaryotes. 
Mutations 
Germinal 
More than 30 different pathogenic variants have 
been reported. MSH6 mutations are responsible of 8-
10% of cases of Lynch Syndrome. Nonsense, 
missense and splice-site mutations predominate, 
whereas large genomic rearrangements are rare. 
Somatic 
The involvement of somatic or epigenetic 
inactivation of MSH6 is rare. 
Gene 
PMS2 (PMS1 homolog 2, mismatch 
repair system component) 
Location 
7p22.1 
DNA/RNA 
Description 
The PMS2 gene is 35,887 bases in length, with 15 
coding exons. 
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Transcription 
The transcribed mRNA has 2771 bps. 3 distinct 
transcripts have been described. 
Pseudogene 
Multiple pseudogenes have been identified at 7p22, 
7p12-13 and 7q11 (Nicolaides et al., 1995). 
Protein 
Description 
Size: 862 aminoacids; Molecular Mass: 95,797 Da. 
It contains a region of homology with other MutS or 
MutL homologs, comprising a region of 150 
aminoacids encompassing a putative helix-turn-
helix domain associated with an adenine nucleotide 
and magnesium binding sites. 
Expression 
Ubiquitous. 
Localisation 
Nucleoplasm. 
Function 
The PMS2 protein dimerizes with MLH1 to form 
MutL alpha, a component of the post-replicative 
DNA mismatch repair (MMR) system. The MutL 
alpha heterodimer possesses an endonucleolytic 
activity that is activated following the recognition of 
DNA mismatches and insertion/deletion loop by 
MutS alpha (composed of MSH2 and MSH6) or 
MutS beta (composed of MSH2 and MSH3). MutL-
MutS complex is responsible for the recruitment of 
other proteins involved in MMR. 
Homology 
The PMS2 gene is homolog to yeast mutator gene 
(bacterial mutL) and PMS2 homologs are also 
present in eukaryotes. 
Mutations 
Germinal 
Germline pathogenic variants in PMS2 are rare and 
are responsible of 2-8% cases of Lynch Syndrome. 
Single nucleotide variants and large gene 
rearrangements have been reported. Large 
rearrangements may constitute >20% of the 
alterations. 
Somatic 
The involvement of somatic or epigenetic 
inactivation of PMS2 is rare. 
Gene 
EPCAM (tumor-associated calcium 
signal transducer 1) 
Location 
2p21 
DNA/RNA 
Description 
The EPCAM gene is 42,444 bases in length, with 9 
coding exons. 
Transcription 
The transcribed mRNA has 1731 bps. 3 distinct 
transcripts have been described. 
Pseudogene 
One pseudogene in 4q34.3. 
Protein 
Description 
Size: 314 aminoacids; Molecular Mass: 34,932 Da. 
It contains a thyroglobulin type 1 repeat, two 
epidermal growth factor-like extracellular domains, 
one single transmembrane domain, one small 
intercellular domain (EpICD), that alone is sufficient 
to induce proliferation signals and PDZ-domain 
identified in its C-terminal end. 
Expression 
Highly and selectively expressed by undifferentiated 
rather than differentiated embryonic stem cells. 
Levels rapidly diminish as soon as embryonic stem 
cells differentiate. Expressed in almost all epithelial 
cell membranes but not on mesodermal or neural cell 
membranes (Litvinov et al., 1996). 
Localisation 
Plasma membrane; baso-lateral in normal cells; 
redistribution on entire plasma membrane in vitro 
and in carcinoma cells. 
Function 
This gene encodes a carcinoma-associated antigen 
and functions as a hemophilic calcium-independent 
cell adhesion molecule. EPCAM plays also a role in 
embryonic stem cell proliferation and 
differentiation. 
Homology 
EPCAM homologs are also present in eukaryotes. 
Mutations 
Germinal 
Deletions involving the transcription termination 
signal of EPCAM can lead to inactivation of the 
MSH2 promoter through hypermethylation and, 
therefore, are a rare cause of Lynch Syndrome. Other 
EPCAM pathogenic variants that do not affect the 
transcription termination signal cause autosomal 
recessive congenital tufting enteropathy. 
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